Narrative Update • Jun 26
Have your own idea? Try our Stock Screener
U.K. (FTSE) Life Sciences Industry Analysis
UpdatedJul 07, 2026
DataAggregated Company Financials
Companies7
- 7D2.5%
- 3M6.5%
- 1Y-10.2%
- YTD-1.2%
Over the last 7 days, the Life Sciences industry has dropped 1.2%, driven by a pullback from Oxford BioDynamics of 27%. The industry has fallen 13% in the last year. As for the next few years, earnings are expected to grow by 57% per annum.
Industry Valuation and Performance
Has the U.K. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 07 Jul 2026 | UK£1.4b | UK£323.1m | -UK£164,731,254.00 | 1278.8x | -8.7x | 4.4x |
| Thu, 04 Jun 2026 | UK£1.5b | UK£323.0m | -UK£166,018,254.00 | 1335.5x | -9.3x | 4.8x |
| Sat, 02 May 2026 | UK£1.3b | UK£318.2m | -UK£167,469,254.00 | n/a | -7.9x | 4.2x |
| Mon, 30 Mar 2026 | UK£1.3b | UK£324.0m | -UK£161,423,254.00 | 8.4x | -8.2x | 4.1x |
| Wed, 25 Feb 2026 | UK£1.5b | UK£304.7m | -UK£159,511,254.00 | 10.9x | -9.4x | 4.9x |
| Fri, 23 Jan 2026 | UK£1.9b | UK£304.6m | -UK£159,441,254.00 | 7.7x | -12x | 6.3x |
| Sun, 21 Dec 2025 | UK£1.4b | UK£304.6m | -UK£159,441,254.00 | 9.5x | -8.9x | 4.7x |
| Tue, 18 Nov 2025 | UK£1.5b | UK£304.3m | -UK£163,156,254.00 | 8.1x | -8.9x | 4.8x |
| Thu, 16 Oct 2025 | UK£1.6b | UK£304.3m | -UK£163,156,254.00 | 9.6x | -9.6x | 5.1x |
| Sat, 13 Sep 2025 | UK£1.8b | UK£313.5m | -UK£158,190,352.00 | 6.2x | -11.4x | 5.8x |
| Mon, 11 Aug 2025 | UK£2.3b | UK£291.9m | -UK£160,968,352.00 | 6.9x | -14.3x | 7.9x |
| Wed, 09 Jul 2025 | UK£1.6b | UK£291.9m | -UK£160,968,352.00 | 6.5x | -9.9x | 5.5x |
| Fri, 06 Jun 2025 | UK£1.6b | UK£319.4m | -UK£190,729,880.80 | 6.9x | -8.2x | 4.9x |
| Sun, 04 May 2025 | UK£1.7b | UK£314.0m | -UK£192,459,514.70 | 11.3x | -8.7x | 5.3x |
| Tue, 01 Apr 2025 | UK£1.4b | UK£315.8m | -UK£186,525,795.85 | 5.2x | -7.6x | 4.5x |
| Thu, 27 Feb 2025 | UK£1.6b | UK£306.2m | -UK£194,997,887.52 | 6.2x | -8.3x | 5.3x |
| Sat, 25 Jan 2025 | UK£2.0b | UK£306.8m | -UK£195,445,659.60 | 7.6x | -10.5x | 6.7x |
| Mon, 23 Dec 2024 | UK£2.0b | UK£306.6m | -UK£195,263,763.36 | 7.7x | -10.2x | 6.5x |
| Wed, 20 Nov 2024 | UK£1.8b | UK£305.6m | -UK£193,419,551.44 | 9.3x | -9.2x | 5.8x |
| Fri, 18 Oct 2024 | UK£2.0b | UK£304.6m | -UK£192,458,244.10 | 11.2x | -10.4x | 6.6x |
| Sun, 15 Sep 2024 | UK£2.0b | UK£301.9m | -UK£190,970,145.50 | 11x | -10.6x | 6.7x |
| Tue, 13 Aug 2024 | UK£1.8b | UK£296.7m | -UK£189,145,970.10 | 12.3x | -9.6x | 6.2x |
| Thu, 11 Jul 2024 | UK£1.6b | UK£295.4m | -UK£189,863,838.15 | 11.5x | -8.3x | 5.4x |
| Sat, 08 Jun 2024 | UK£1.6b | UK£295.7m | -UK£189,852,799.62 | 11.4x | -8.4x | 5.4x |
| Mon, 06 May 2024 | UK£1.6b | UK£292.8m | -UK£188,897,474.93 | 6902.8x | -8.3x | 5.3x |
| Wed, 03 Apr 2024 | UK£1.7b | UK£319.2m | -UK£191,505,488.91 | 69.2x | -8.9x | 5.3x |
| Fri, 01 Mar 2024 | UK£1.8b | UK£285.9m | -UK£189,317,667.48 | 6786x | -9.7x | 6.5x |
| Sun, 28 Jan 2024 | UK£2.7b | UK£450.2m | -UK£176,590,140.00 | 65.1x | -15.3x | 6x |
| Tue, 26 Dec 2023 | UK£3.1b | UK£450.0m | -UK£174,026,893.00 | 52.7x | -18.1x | 7x |
| Thu, 23 Nov 2023 | UK£3.0b | UK£455.8m | -UK£168,850,712.00 | 49.9x | -17.8x | 6.6x |
| Sat, 21 Oct 2023 | UK£3.1b | UK£458.7m | -UK£165,663,282.00 | 48.3x | -18.5x | 6.7x |
| Mon, 18 Sep 2023 | UK£3.1b | UK£440.6m | -UK£167,135,947.00 | 67.5x | -18.8x | 7.1x |
| Wed, 16 Aug 2023 | UK£3.2b | UK£476.2m | -UK£126,550,727.00 | 70.6x | -25.5x | 6.8x |
| Fri, 14 Jul 2023 | UK£3.0b | UK£475.6m | -UK£123,993,961.00 | 66.1x | -24.5x | 6.4x |
Price to Earnings Ratio
-24.5x
Current Industry PE
- Investors are pessimistic on the British Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.8x is higher than the industry's current PS ratio of 4.3x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Revenues have also declined 12% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | 1.66% | |
| Healthcare | -0.49% | |
| Life Sciences | 2.54% | |
| Clinical Research and Equipment | 2.54% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies | UK£1.26 | 2.9% +UK£34.1m | -11.7% | PS5.5x | |
| HVO hVIVO | UK£0.071 | 4.4% +UK£2.1m | -31.1% | PS1x | |
| DXRX Diaceutics | UK£1.47 | 1.4% +UK£1.7m | 25.8% | PE1278.8x | |
| FAB Fusion Antibodies | UK£0.12 | 2.2% +UK£312.6k | 82.5% | PS9x |